Capsugel Expands LMP Drug Delivery Platform

Capsugel’s lipid multi-particulate (LMP) technology drug delivery platform is now commercially available for multiple applications, including bioavailability enhancement, taste-masking and modified release for pharmaceutical and health and nutrition products. The company’s LMP technology is based on its melt-spray congeal (MSC) processing and combines lipid-based formulations (LBF) with the functionality of a multi-particulate dosage form in one offering.
 
MSC processing for LMP production is currently available at Capsugel’s manufacturing site in Bend, OR, and a commercial-scale facility with MSC processing and capsule-filling capability was recently installed at its location in Greenwood, SC.
 
“With our LMP technology, Capsugel is again employing its advanced science and engineering to provide clients with innovative options to achieve their target product profiles and commercial objectives,” said Keith Hutchison, Ph.D., senior vice president, R&D, Capsugel. “LMP technology already has a commercialized pharmaceutical product, and we have developed several product applications in the H&N marketplace. Given its performance and flexibility, we expect LMPs to become the right solution to address many client project challenges.”